Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure
MACE, heart failure composite end point, cardiovascular death, and all-cause death all improved with semaglutide for patients with versus without heart failure
Weight-Loss Drug Zepbound Now in Single-Dose Vials at Half the Price
Team-Based Documentation Can Increase Visit Volume, Cut Documentation Time
High-intensity adopters had reduction in documentation for full postadoption periods and following learning period
Radiotherapy Dose to Cardiac Substructures Linked to Arrhythmias
After adjustment for baseline cardiovascular risk, pulmonary vein volume receiving 5 Gy linked to atrial fibrillation
After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide
If all newly eligible beneficiaries receive semaglutide, maximum Medicare spending could be $34 to $145 billion annually
Awareness of Unruptured Aneurysm Diagnosis Increases Risk for Mental Illness
Incidence rate of mental illness higher among those with UIA, especially in younger age groups
Prevalence of HTN Increases With Neighborhood Disadvantage
Higher hypertension rate and lower treatment rate seen for highest versus lowest ADI quintile neighborhood
Women Have Lower Risk for Postoperative A-Fib After Cardiac Surgery
Men and women with poAF have higher risk for death than those without poAF, with higher risk seen for women than men
Exposure to Tobacco on TV, Streaming Varies by Sociodemographics
Disparities in exposure seen by race or ethnicity, education level, and smoking status
Study Reveals Heart Failure Risks in American Indian Communities
Older age, smoking, macroalbuminuria, microalbuminuria, previous MI, diabetes, and glycated hemoglobin predict risk
